Cancer Vaccine

N-803 and BCG for Bladder Cancer

UCLA Department of Urology, Los Angeles, CA
N-803 and BCG +1 morePhase 2 & 3RecruitingLed by Karim Chamie, MDResearch Sponsored by ImmunityBio, Inc.

Study Summary

This trial is testing a new drug, N-803, for people with bladder cancer that has not responded to BCG treatment. Patients will receive the new drug through a urinary catheter weekly for 6 weeks, followed by maintenance treatment every 3 or 6 weeks for up to 3 years.

Eligible Conditions
  • Bladder Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease-Free Rate
Secondary outcome measures
Complete Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BCG+N-803Experimental Treatment2 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Find a site

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
59 Previous Clinical Trials
4,891 Total Patients Enrolled
Karim Chamie, MDPrincipal Investigator
University of California, Los Angeles

Media Library

BCG (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03022825 — Phase 2 & 3
Bladder Cancer Research Study Groups: BCG+N-803
Bladder Cancer Clinical Trial 2023: BCG Highlights & Side Effects. Trial Name: NCT03022825 — Phase 2 & 3
BCG (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03022825 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the precedent for N-803 and BCG research?

"Right now, there are a 20 active research studies being conducted on N-803 and BCG. Out of those 20, 3 are in Phase 3. However, the majority of clinical trials taking place for N-803 and BCG are being conducted in Ann Arbor, Michigan. In total, there are 508 medical research sites running these sorts of experiments."

Answered by AI

Could you tell me how many different facilities are coordinating this research project?

"The primary locations for this clinical trial are UCLA Department of Urology in Los Angeles, California, Moffitt Cancer Center in Tampa, Florida, and Karmanos Cancer Institute in Detroit, New York. There are also 15 other locations participating in this trial."

Answered by AI

Are people with the specified medical condition still being recruited for this research project?

"That is accurate. The listing on currently states that the trial is looking for 200 individuals to participate. The trial was first posted on 6/2/2017 and the most recent update was on 10/26/2022. There will be 15 sites enrolling patients."

Answered by AI
~35 spots leftby Apr 2025